Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

Enzo has been awarded a license to provide clinical diagnostic services in Pennsylvania, which could help the eventual uptake of ColonSentry, a PCR-based colon cancer risk-stratification test manufactured by Canadian firm GeneNews and for which Enzo has exclusive distribution rights in New York and New Jersey.

Petricoin said the database could help physicians make better treatment decisions, aid pharmaceutical firms' drug-development efforts, and uncover new indications for existing therapies.

While Genomic Health projects "more modest" growth for its legacy node-negative breast cancer business over the next year, newer markets in which the company is still working to secure reimbursement still represent a significant opportunity for expansion in the years ahead.

The permit allows DiagnoCure to use its colorectal cancer test on samples originating from New York State, potentially opening a significant market for the test.

Exact Sciences gains exclusive, worldwide rights to DNA methylation markers, which will be used in the firm's colorectal cancer test.

The test, which amplifies and detects methylated Septin9 DNA from patient plasma samples, has been shown to identify a higher proportion of colorectal cancers than Quest Diagnostics' laboratory-developed test, called ColoVantage; as well as CE-marked in vitro diagnostics offered in Europe by Epigenomics and Abbott.

The Mayo team is evaluating different capture and sequencing techniques for use in molecular diagnostics. In a recent study the researchers tested NimbleGen's capture array with both the Roche 454 GS FLX and Illumina GA. Next up will be Agilent's in-solution capture technique, RainDance's microdroplet PCR technology, and standard PCR enrichment.

Pharmacogenomics Reporter took stock of industry expectations ahead of FDA's upcoming meeting to discuss the agency's strategy for regulating laboratory-developed tests.

The agreement formalizes a marketing partnership with GeneDiagnostics to sell the ColonSentry test in certain parts of China.

Potsdam-based Signature Dx plans to launch by the fourth quarter of this year two array-based in vitro diagnostics for colorectal cancer. The company will first launch the tests in Europe and intends to seek US regulatory approval at an unspecified time in the future.


The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.